Rob J van Klaveren
Affiliation: Erasmus MC
Country: The Netherlands
- Stem cells and the natural history of lung cancer: implications for lung cancer screeningRob J van Klaveren
Department of Pulmonology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Clin Cancer Res 15:2215-8. 2009..Because the natural history of lung cancer is only partly elucidated, conclusions on the impact of overdiagnosis in lung cancer screening are premature...
- Complications following lung surgery in the Dutch-Belgian randomized lung cancer screening trialSusan C Van't Westeinde
Department of Pulmonology, Erasmus MC Rotterdam, Rotterdam, Netherlands
Eur J Cardiothorac Surg 42:420-9. 2012....
- The role of conventional bronchoscopy in the workup of suspicious CT scan screen-detected pulmonary nodulesSusan C van 't Westeinde
Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
Chest 142:377-84. 2012..If a bronchoscopic evaluation could be eliminated, the cost-effectiveness of a screening program could be enhanced and the potential harms of bronchoscopy avoided...
- Screening and early detection of lung cancerSusan C Van't Westeinde
Department of Pulmonology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
Cancer J 17:3-10. 2011..Finally, the approach of (noninvasive) biomarker testing in the blood, exhaled breath, sputum, and bronchoscopic specimen is reviewed...
- The role of the ¹⁸f-fluorodeoxyglucose-positron emission tomography scan in the Nederlands Leuvens Longkanker screenings Onderzoek lung cancer screening trialSusan C Van't Westeinde
Department of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
J Thorac Oncol 6:1704-12. 2011..In computed tomography lung cancer screening programs, up to 30% of all resections are futile...
- How to deal with incidentally detected pulmonary nodules less than 10mm in size on CT in a healthy personSusan C Van't Westeinde
Department of Pulmonology, Erasmus MC Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
Lung Cancer 60:151-9. 2008..Growing lesions with a volume doubling time <400 days require further work-up and diagnosis, otherwise an annual repeat scan to assess growth is recommended...
- Mass spectrometry analyses of κ and λ fractions result in increased number of complementarity-determining region identificationsIngrid Broodman
Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands
Proteomics 12:183-91. 2012..The number of CDRs and κ:λ ratio was statistically similar in both cases and controls. Molecular dissection of IgG identifies significantly more CDRs, which increases the likelihood of finding lung cancer-related CDR sequences...
- Proper treatment selection may improve survival in patients with clinical early-stage nonsmall cell lung cancerOzcan Birim
Department of Cardiothoracic Surgery, Erasmus MC Rotterdam, Rotterdam, The Netherlands
Ann Thorac Surg 80:1021-6. 2005..In this report, treatment selection and the outcome of both surgically and nonsurgically treated patients is evaluated...
- Management of lung nodules detected by volume CT scanningRob J van Klaveren
Department of Pulmonology, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
N Engl J Med 361:2221-9. 2009....
- Peptides from the variable region of specific antibodies are shared among lung cancer patientsDominique de Costa
Department of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands
PLoS ONE 9:e96029. 2014..With our Fab-purification combined Orbitrap-mass-spectrometry approach, we found peptides from the variable-parts of antibodies which are shared among lung cancer patients. ..
- Pemetrexed maintenance therapy in patients with malignant pleural mesotheliomaDebby P M van den Bogaert
Department of Pulmonary Medicine, Erasmus MC Daniel den Hoed Cancer Clinic, Rotterdam, The Netherlands
J Thorac Oncol 1:25-30. 2006..To investigate the toxicity and effectiveness of pemetrexed maintenance therapy (PMT) in patients with malignant pleural mesothelioma (MPM)...
- Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON)Carola A Van Iersel
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
Int J Cancer 120:868-74. 2007..When pooling with Danish trial data (n = +/-4,000) NELSON is the only trial without screening in controls that is expected to have 80% power to show a lung cancer mortality reduction of at least 25% 10 years after randomisation...
- Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking StatusIngrid Broodman
Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands
Cancer Immunol Res 4:165-72. 2016..Autoantibody studies benefit from a comparison to a well-controlled population, stratified for smoking habit. Cancer Immunol Res; 4(2); 165-72. ©2015 AACR. ..
- Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial)Karien A M van den Bergh
Department of Public Health, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands
Cancer 113:396-404. 2008..In the current study, the authors assessed the discomfort associated with CT scanning and the subsequent wait for results and health-related quality of life (HRQoL) over time...
- Survival after pathological stage IA nonsmall cell lung cancer: tumor size mattersOzcan Birim
Department of Cardiothoracic Surgery, Rotterdam, The Netherlands
Ann Thorac Surg 79:1137-41. 2005..This study evaluates prognostic factors for survival in completely resected pathological stage IA nonsmall cell lung cancer with special emphasis on tumor size and assesses tumor recurrence rate by actual and actuarial analysis...
- Lung cancer screening by spiral CT. What is the optimal target population for screening trials?Rob J van Klaveren
Department of Pulmonology, Erasmus Medical Centre, University Hospital Rotterdam, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
Lung Cancer 38:243-52. 2002..The inadequacy of the unit 'Pack-Years' (PY) to estimate the individual lung cancer risk is recognised, and future initiatives to develop an appropriate lung cancer risk model are encouraged...
- Limited contamination in the Dutch-Belgian randomized lung cancer screening trial (NELSON)Eleonora Baecke
Department of Public Health, Erasmus MC University Medical Center Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Lung Cancer 69:66-70. 2010..In conclusion, the rate of contamination among male subjects of the control arm of the NELSON trial is low and is not likely to jeopardize the power of the trial...
- Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheterLeon M van den Toorn
Department of Pulmonary Diseases, Erasmus MC Daniel den Hoed Cancer Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
Lung Cancer 50:123-7. 2005..We conclude that a chronic indwelling catheter is a very useful tool in the management of recurrent malignant pleural effusions. Treatment can be accomplished completely at home, whereas complications are rare...
- Ultrafast selective quantification of methotrexate in human plasma by high-throughput MALDI-isotope dilution mass spectrometryRoland J W Meesters
Laboratories of Neuro Oncology and Clinical and Cancer Proteomics, Department of Neurology, University Medical Center Rotterdam ErasmusMC, Dr Molewaterplein 50, Room Ee 1981, 3015 GE Rotterdam, The Netherlands
Bioanalysis 3:1369-78. 2011..2→308.2, 458.2→311.2, 471.2→324.2 and 474.2→327.2 for methotrexate, methotrexate-d3, 7-hydroxymethotrexate and 7-hydroxymethotrexate-d3, respectively...
- A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patientsRoland J W Meesters
Department of Neurology, Laboratory of Neuro Oncology and Clinical and Cancer Proteomics, University Medical Center Rotterdam ErasmusMC, Dr Molewaterplein 50, Room Ee 1981, 3015 GE Rotterdam, The Netherlands
Anal Bioanal Chem 398:2943-8. 2010..7 (1.4) and 142.7 (20.3) pmol/μL (SD). The newly developed mass spectrometric assay is applicable for (routine) therapeutic drug monitoring of pemetrexed concentrations in plasma from non-small cell lung cancer patients...
- Informed decision making does not affect health-related quality of life in lung cancer screening (NELSON trial)Karien A M van den Bergh
Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Eur J Cancer 46:3300-6. 2010..This is the first study in cancer screening to explore this association in subjects participating in a lung cancer computed tomography (CT) screening trial...
- Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesotheliomaRob J van Klaveren
Department of Pulmonology, Erasmus University Medical Center, Rotterdam, Netherlands
Lung Cancer 43:63-9. 2004....
- High relapse-free survival after preoperative and intraoperative radiotherapy and resection for sulcus superior tumorsAlbertus N van Geel
Department of Surgical Oncology, Erasmus Medical Center Daniel den Hoed, Rotterdam, The Netherlands
Chest 124:1841-6. 2003..Relapse-free survival in patients with sulcus superior tumors...
- Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumorsJoost J Nuyttens
Department of Radiation Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Radiother Oncol 102:383-7. 2012....
- Sequencing and quantifying IgG fragments and antigen-binding regions by mass spectrometryDominique de Costa
Department of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands
J Proteome Res 9:2937-45. 2010..From these results, we conclude that the identification of a CDR signature as biomarker for autoimmune diseases and cancer without prior knowledge of the antigen is feasible...
- Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapySuresh Senan
Department of Radiation Oncology, University Hospital Rotterdam, Rotterdam, The Netherlands
Int J Radiat Oncol Biol Phys 54:999-1006. 2002..To establish the recurrence patterns when elective mediastinal irradiation was omitted, patients with Stage III non-small-cell lung cancer were treated with sequential chemotherapy (CHT) and involved-field radiotherapy (RT)...